Sino Biopharmaceutical Limited

SEHK:1177 Stock Report

Market Cap: HK$75.0b

Sino Biopharmaceutical Future Growth

Future criteria checks 3/6

Sino Biopharmaceutical is forecast to grow earnings and revenue by 16.5% and 8.8% per annum respectively. EPS is expected to grow by 17.2% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

16.5%

Earnings growth rate

17.18%

EPS growth rate

Pharmaceuticals earnings growth11.0%
Revenue growth rate8.8%
Future return on equity10.21%
Analyst coverage

Good

Last updated27 May 2025

Recent future growth updates

Recent updates

Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04

May 23
Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04

Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

May 06
Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Apr 30
Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Apr 27
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Apr 06
Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Mar 23
Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Jan 13
Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Dec 08
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Earnings and Revenue Growth Forecasts

SEHK:1177 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202738,7163,8836,6429,13118
12/31/202635,1383,5065,6088,24723
12/31/202532,0233,1955,0886,94523
12/31/202428,8661,9205,2216,615N/A
6/30/202427,7902,1425,3456,473N/A
3/31/202426,9951,9954,9686,269N/A
12/31/202326,1991,8474,5916,066N/A
6/30/202325,1161,2543,3144,987N/A
3/31/202325,5711,6564,0175,626N/A
12/31/202226,0262,0594,7196,265N/A
9/30/202228,2415,2964,8956,622N/A
6/30/202227,7018,0495,0716,980N/A
3/31/202227,21513,655N/AN/AN/A
12/31/202126,86114,6083,4995,366N/A
9/30/202126,12912,465N/AN/AN/A
6/30/202125,35310,0114,3376,105N/A
3/31/202124,6683,809N/AN/AN/A
12/31/202023,6472,7713,5375,325N/A
9/30/202023,0392,302N/AN/AN/A
6/30/202024,3542,5581,8273,373N/A
3/31/202024,2482,781N/AN/AN/A
12/31/201924,2342,7623,6225,325N/A
9/30/201924,4799,101N/AN/AN/A
6/30/201923,6919,1254,7746,543N/A
3/31/201922,4449,132N/AN/AN/A
12/31/201820,8899,0463,4175,094N/A
9/30/201819,1032,567N/AN/AN/A
6/30/201817,0622,436N/A2,572N/A
3/31/201815,6092,363N/AN/AN/A
12/31/201714,8192,171N/A3,733N/A
9/30/201714,4912,115N/AN/AN/A
6/30/201714,2581,862N/A4,773N/A
3/31/201713,8991,789N/AN/AN/A
12/31/201613,5431,637N/A2,995N/A
9/30/201613,2711,674N/AN/AN/A
6/30/201612,8581,604N/A1,757N/A
3/31/201612,5071,575N/AN/AN/A
12/31/201512,1891,490N/A1,919N/A
9/30/201512,0301,432N/AN/AN/A
6/30/201511,1241,447N/A1,973N/A
3/31/201510,5521,263N/AN/AN/A
12/31/20149,9001,210N/A1,840N/A
9/30/20149,2051,074N/AN/AN/A
6/30/20148,876951N/A2,000N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1177's forecast earnings growth (16.5% per year) is above the savings rate (2.6%).

Earnings vs Market: 1177's earnings (16.5% per year) are forecast to grow faster than the Hong Kong market (10.4% per year).

High Growth Earnings: 1177's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1177's revenue (8.8% per year) is forecast to grow faster than the Hong Kong market (8.3% per year).

High Growth Revenue: 1177's revenue (8.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1177's Return on Equity is forecast to be low in 3 years time (10.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 03:22
End of Day Share Price 2025/05/28 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sino Biopharmaceutical Limited is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Justin LiuBNP Paribas Securities (Asia)
Sharon ShiBOCI Research Ltd.